Welcome to our dedicated page for Guided Thera news (Ticker: GTHP), a resource for investors and traders seeking the latest updates and insights on Guided Thera stock.
Guided Therapeutics, Inc. (OTCQB: GTHP) is a medical device company in the surgical and medical instrument manufacturing industry that focuses on early disease detection using patented biophotonic technology. Its news flow centers on the development, clinical evaluation and commercialization of the LuViva® Advanced Cervical Scan, a non-invasive device designed to detect cervical disease instantly at the point of care.
News updates for Guided Therapeutics frequently cover clinical milestones, such as progress and preliminary findings from its U.S. FDA pivotal clinical trial and study results used to support an application to the Chinese National Medical Products Administration. These reports describe how LuViva is being evaluated for its ability to detect cervical precancers and cancers that may be missed by current screening and diagnostic practices.
Investors and observers can also find announcements about distribution and commercialization agreements in multiple regions. Recent press releases describe purchase orders, payments and shipments of LuViva devices and single-use components to partners in China, including Shandong Yaohua Medical Instrument Corporation, Hangzhou Dongye Medical Technology Company Ltd and Yuanshuo Medical Instruments Corporation, as well as an order for devices and disposables for the government healthcare system in Sulawesi, Indonesia.
On this news page, readers can follow company statements on regulatory submissions, clinical trial enrollment and analysis, and commercial arrangements related to LuViva. These updates provide insight into how Guided Therapeutics is advancing its cervical disease detection technology through studies, regulatory processes and partnerships. For those tracking GTHP, the news stream offers context on the company’s progress in moving from investigational use and clinical evaluation toward broader deployment of its diagnostic platform, subject to regulatory review and market adoption.
Guided Therapeutics (OTCQB: GTHP) announced a new purchase order worth $530,695 from its Chinese partner, Shandong Yaohua Medical Instrument Corporation (SMI). This order follows a larger existing order of $2.5 million. The new order indicates progress towards FDA approval of LuViva, expected in early 2022. Guided Therapeutics anticipates revenues from China to exceed $1 million in 2021. Cervical cancer remains a significant health issue in China, highlighting the potential market for their advanced detection technology.
Guided Therapeutics, Inc. (OTCQB: GTHP) has opened a new LuViva Reference and Training Center in Budapest, Hungary, in partnership with Newmars Technologies. This center aims to train European physicians on the use of LuViva, a device for early cervical disease detection. The CE Mark allows commercialization across 27 EU countries, reaching 229 million women. New clinical data will be published next year indicating LuViva's ability to detect cervical cancer earlier than traditional tests. The company anticipates significant device orders in 2021, bolstered by the ongoing Russian certification process.